Tissera Inc. Appoints Professor Yair Reisner, of the Weizmann Institute of Science in Israel to Chair Its Scientific Advisory Board.

Business Editors/Health/Medical Writers

TEL AVIV, Israel--(BUSINESS WIRE)--March 31, 2004

Tissera, Inc. (OTCBB:TSSR), a biotechnology company dedicated to developing novel tissue precursor regeneration technologies to address a myriad of fatal illnesses where an organ transplantation is necessary, announced today that Professor Yair Reisner of The Weizmann Institute of Science in Israel has been appointed Chairman of the Company's Scientific Advisory Board (SAB).

"Professor Riesner's international recognition as a leader in transplantation immunology, makes his appointment as Chairman of the SAB a strategically important one for Tissera," said Dr. Vicki Rabenou, Tissera's CEO. "Professor Reisner, a world-renowned expert in immunology, brings a wide spectrum of immunology, tissue regeneration, and transplantation experience to our SAB and will provide guidance to Tissera as we are advancing with our Research and Development."

Prof. Reisner, a renowned expert in transplantation technology, holds the Henry Drake chair of Immunology at the Weizmann Institute of Science. He earned his M.Sc. at the University of California, Berkeley and his Ph.D. at the Weizmann Institute of Science, Rehovot, Israel. Prof. Reisner has pioneered and popularized techniques for bone marrow transplantation with partially matched donor tissue. He is a member of the Advisory Committee of the American Society of Hematology Scientific committee on transplantation Biology and has been a visiting professor at the Memorial Sloane Kettering Cancer Center, Harvard University and Columbia University.

Prof. Reisner has published widely in leading scientific journals and serves as an Associate Editor for the Journal for Experimental Hematology, as a co-editor of an electronic quarterly on haploidentical bone marrow transplantation (www.haplo.org) and on the editorial board of a number of publications. Since 1993 Prof. Reisner, who was a founder of XTL Biopharmaceuticals Ltd., has served as a member of the Scientific Advisory Board of that company. XTL has developed fully human monoclonal antibodies for the treatment of hepatitis B and C.

About Tissera

Tissera is a biotechnology company dedicated to the development of novel tissue precursor regeneration technologies for treating gene deficiencies and diseases in which organ transplantation is necessary, while minimizing the dosage of immunosuppressive drugs. Tissera licensed the worldwide exclusive rights to the technology developed by Professor Yair Reisner at the Weizmann Institute of Science in Israel. In this research, scientists successfully implanted embryonic human and porcine kidney precursor tissues in mice, which grew into functional kidneys. This research was published in Nature Medicine and attracted worldwide scientific and media attention.

Safe Harbor Statement

"Statements in this document that are not purely historical are forward-looking statements. Forward-looking statements in this release include statements regarding our developing technology into a useful product, our moving forward with our plans for trials, and our plans to expand the Company's infrastructure. Actual outcomes and our actual results could differ materially from those in such forward-looking statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to further finance our plans and unforeseen technical difficulties in developing our technology, which could among other things, delay or prevent product development and our planned results. For further risk factors see the Company's 10-KSB filed with the SEC for our latest fiscal year."